Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4)
Latest & greatest articles for folic acid
The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on folic acid or other clinical topics then use Trip today.
This page lists the very latest high quality evidence on folic acid and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.
What is Trip?
Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.
Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.
As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.
For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via email@example.com
New Perspective on Impact of FolicAcid Supplementation during Pregnancy on Neurodevelopment/Autism in the Offspring Children - A Systematic Review. It has been conclusively established that folicacid supplementation prior to and during early pregnancy (up to 12 weeks of gestation) can prevent neural tube defects (NTDs). We hypothesized that folate effects may extend from neuro-structural defects to alterations in neuro-behavioural and emotional skills including autism spectrum disorders (ASDs (...) ) and other developmental disorders. The objective of this review was to comprehensively evaluate evidence on the impact of folicacid on neurodevelopment other than NTDs. We conducted an online search of relevant literature compiled by the National Library of Medicine from Medline and EMBASE (searched on Dec 31, 2014: http://www.ncbi.nlm.nih.gov/entrez/query/fcgi and http://www.elsevier.com/online-tools/embase). We first created 3 files (search restricted to English literature) using the following key
Effect of folicacid supplementation on preterm delivery and small for gestational age births: A systematic review and meta-analysis. To investigate the effect of folicacid (FA) supplementation on the risks of preterm delivery (PTD) and small for gestational age births (SGA).Cohort studies were identified from MEDLINE, EMBASE, the Cochrane Library, CINAHL, and CBM from inception to January 2015.Healthy women who want to get pregnancy or being pregnant.PTD and SGA.The association of FA and PTD (...) was significant when supplement initiated after pregnancy (RR=0.68, 95%CI, 0.52-0.90), whereas no effect was founded if the initiation time was before conception (RR=0.89, 95%CI, 0.80-1.01). The results for the association between FA supplementation and SGA showed significant protective effect: initiated before conception (RR=0.70, 95%CI, 0.57-0.85) and initiated after conception (RR=0.84, 95%CI, 0.81-0.89).Folicacid supplementation is associated with a significant reduction on the risk of PTD when initiated
A Meta-Analysis of the Relationship Between Maternal FolicAcid Supplementation and the Risk of Congenital Heart Defects. Controversial opinions exist with respect to the relationship between maternal folicacid (FA) supplementation and birth prevalence of congenital heart defects (CHDs).Eligible articles were retrieved by searching databases, including PubMed, Cochrane library, EMBASE, CNKI, and WanFang up to September 2015. A meta-analysis was performed to evaluate the effects of FA on CHDs
The evaluation of serum homocysteine, folicacid, and vitamin B12 in patients complicated with preeclampsia Increased plasma homocysteine may be associated with adverse pregnancy outcomes, such as preeclampsia. The aim of this study was to determine the plasma homocysteine, serum folate, and vitamin B12 levels in preeclamptic pregnant women.This case-control study was conducted in 2016 in Ahwaz on 51 pregnant women with preeclampsia and 51 healthy pregnant women of the same gestational age, who (...) served as controls. The case group also was subdivided into severe and non-severe preeclampsia. Patients' data were collected through a questionnaire and medical records. Serum homocysteine, folicacid, and vitamin B12 were analyzed using chemiluminescent assay. The results were compared between two groups. Statistical analyses were done using IBM-SPSS 20.0. A Kolmogorov-Smirnov test, independent samples t-test, Mann-Whitney test, and Chi-square test were used for data analysis.No different
Effect of FolicAcid therapy on Homocysteine Level in patients with Atherosclerosis or Buergerâ€™s Disease and in Healthy individuals: A clinical trial Hyperhomocysteinemia is considered a risk factor for atherosclerosis and some other vascular diseases such as Buerger's disease.The aim of this study was to measure the Homocysteine levels in 3 different groups of participants (Buerger's disease, atherosclerosis patients, and healthy cases) and determine the therapeutic effect of folicacid (...) and after 12 weeks of folicacid (5mg/day) therapy. The data analysis used fo data analysis was a Chi square and t-test or their non-parametrical equivalents for data analysis by means of Statistical Package for the Social Sciences (SPSS) version 16.The homocysteine levels were found to be significantly higher in patients with Buerger's disease as compared to other groups before treatment with folicacid (Buerger = 21.8 ± 8.5 Mm/L, atherosclerosis = 17.3 ± 6.9, healthy = 13.8 ± 3.1; p < 0.001). After
Efficacy of FolicAcid Therapy on the Progression of Chronic Kidney Disease: The Renal Substudy of the China Stroke Primary Prevention Trial The efficacy of folicacid therapy on renal outcomes has not been previously investigated in populations without folicacid fortification.To test whether treatment with enalapril and folicacid is more effective in slowing renal function decline than enalapril alone across a spectrum of renal function at baseline from normal to moderate chronic kidney (...) disease (CKD) among Chinese adults with hypertension.In this substudy of eligible China Stroke Primary Prevention Trial (CSPPT), 15 104 participants with an estimated glomerular filtration rate (eGFR) 30 mL/min/1.73 m2 or greater, including 1671 patients with CKD, were recruited from 20 communities in Jiangsu province in China.Participants were randomized to receive a single tablet daily containing 10 mg enalapril and 0.8 mg folicacid (n = 7545) or 10 mg enalapril alone (n = 7559).The primary outcome
FolicAcid Supplementation and the Risk of Cardiovascular Diseases: A Meta-Analysis of Randomized Controlled Trials. Results from observational and genetic epidemiological studies suggest that lower serum homocysteine levels are associated with lower incidence of cardiovascular disease (CVD). Numerous randomized controlled trials have investigated the efficacy of lowering homocysteine with folicacid supplementation for CVD risk, but conflicting results have been reported.Three bibliographic (...) databases (Medline, Embase, and the Cochrane Database of Systematic Reviews) were searched from database inception until December 1, 2015. Of the 1933 references reviewed for eligibility, 30 randomized controlled trials involving 82 334 participants were included in the final analysis. The pooled relative risks of folicacid supplementation compared with controls were 0.90 (95% CI 0.84-0.96; P=0.002) for stroke, 1.04 (95% CI 0.99-1.09; P=0.16) for coronary heart disease, and 0.96 (95% CI 0.92-0.99; P
[Meta-analysis on effect of combined supplementation of folicacid, vitamin B12 and B6 on risk of cardio-cerebrovascular diseases in randomized control trials]. To evaluate the effect of the combined supplementation of folicacid, vitamin B12 and B6 on the risk of cardio-cerebrovascular diseases.The literatures of randomized control trials about the relationship between the combined supplementation of folicacid, vitamin B12 and B6 and risk of cardio-cerebrovascular diseases from 1980 to 2014 (...) no effect on the incidence of cardiovascular disease events(RR=1.00, 95% CI: 0.94-1.07)based on 8 studies. The combined supplementation of B vitamins had no effect on the incidence of myocardial infarction(RR= 1.03, 95% CI: 0.94-1.13)based on 9 studies. The combined supplementation of B vitamins could reduce the incidence of stroke by 14%(RR=0.86, 95%CI: 0.78-0.95)based on 9 studies. Compared with the control group, Taking folicacid combined with vitamin B12 and B6 could reduce the level
Effect of folicacid supplementation during pregnancy on gestational hypertension/preeclampsia: A systematic review and meta-analysis. To evaluate the effect of folicacid supplementation during pregnancy on the risk of gestational hypertension/preeclampsia.A systematic review and meta-analysis were conducted. Medline, Embase, Scopus, and the Web of Science were searched from inception to December 2014.Out of 1224 potentially relevant studies, 13 studies met our inclusion criteria (2 randomized (...) controlled trials (RCTs), 10 cohort studies, and 1 case-control study). The pooled relative risk (RR) and 95% confidence interval (CI) of the two RCTs were 0.62 (0.45-0.87) in the trial arm as compared with the placebo arm. The pooled RR was 0.92 (95% CI: 0.79-1.08) for nine cohort studies with available data on folicacid supplementation in pregnancy and gestational hypertension/preeclampsia. Pooled RR was 0.88 (95% CI: 0.76-1.02) for eight cohort studies with available data on folicacid
A combination of omega-3 fatty acids, folicacid and B-group vitamins is superior at lowering homocysteine than omega-3 alone: A meta-analysis. The aim of the study was to assess whether omega-3 polyunsaturated fatty acid supplementation alone or in combination with folicacid and B-group vitamins is effective in lowering homocysteine. The Medline Ovid, Embase and Cochrane databases were searched for randomized-controlled trial studies that intervened with omega-3 supplementation (...) (with or without folicacid) and measured changes in homocysteine concentration. Studies were pooled using a random effects model for meta-analysis. Three different models were analyzed: all trials combined, omega-3 polyunsaturated fatty acid trials, and omega-3 polyunsaturated fatty acids with folicacid and B-group vitamin trials. Nineteen studies were included, consisting of 3267 participants completing 21 trials. Studies were heterogeneous; varying by dose, duration and participant health conditions
FolicAcid Supplementation May Reduce Colorectal Cancer Risk in Patients With Inflammatory Bowel Disease : A Systematic Review and Meta-Analysis. To evaluate the role of folicacid supplementation in colorectal cancer (CRC) chemoprevention in patients with inflammatory bowel disease (IBD).CRC is a serious complication of IBD. Folicacid supplementation has been shown to be chemopreventative in sporadic CRC. Patients with IBD are at risk of folate deficiency though intestinal malabsorption (...) and also competitive inhibition by concurrent sulfasalazine use. To date, there have been several studies reporting on folicacid supplementation in patients with IBD and CRC.We searched electronic databases for studies reporting folicacid use and CRC incidence in patients with IBD. We produced a pooled hazard ratio with 95% confidence intervals using a random-effects model. Preplanned subgroup analyses were performed to explore for any potential sources of heterogeneity.Ten studies reporting on 4517
Folicacid supplementation in pregnancy to prevent preterm birth: a systematic review and meta-analysis of randomized controlled trials. Folicacid (FA) may have a role in the prevention of pregnancy complications. However, the efficacy of FA supplementation in reducing the risk of preterm birth (PTB) is still unclear. The aim of this systematic review with meta-analysis was to evaluate the efficacy of folicacid supplementation during pregnancy to prevent preterm birth (PTB). The research
The impact of MTHFR 677 C/T genotypes on folate status markers: a meta-analysis of folicacid intervention studies. Methylenetetrahydrofolate reductase (MTHFR) is a key folate pathway enzyme with the T variant of the MTHFR gene increasing the risk of low folate status, particularly coupled with low folate intake. As genetic variability of MTHFR influences folate status, it is important to ensure an adequate intake that overrides genetic effects but minimises any adverse effects. Our aim (...) , TT vs. CC) and lower serum folate (2.5 nmol/L, TT vs. CT/CC; 3.6 nmol/L, TT vs. CC). In two studies, the TT groups had mean plasma Hcy >15 μmol/L. Serum folate levels were >7 nmol/L for all genotype groups. After supplementation of 400 up to 1670 μg DFEs of folicacid or folicacid + fortified foods and/or natural food folates for a minimum of 4 weeks, there were no significant differences in plasma homocysteine levels; however, individuals with the TT genotype had a lower serum folate response
[Meta-analysis of clinical trials of folicacid, vitamin B12 and B6 supplementation on plasma homocysteine level and risk of cardiovascular disease]. To evaluate the effects of folicacid, vitamin B(6) and B(12) supplementation on plasma homocysteine level and risk of cardiovascular disease.The databases, including Embase, Pubmed, Ovid, Biosis, China National Knowledge Infra-structure (CNKI), Wanfang Data, VIP Database for Chinese Technical Periodical (VIP), Chinese Biomedical Literature (...) Database (CMB), were searched to identify random control trials between February 1994 to February 2014 on the effect of folicacid, vitamin B(6) and B(12) supplementation on plasma homocysteine level and risk of cardiovascular disease. The screening, data extraction and quality assessment were conducted in accordance with the inclusion and exclusion criteria by two reviewers independently. The software Review Manager 5.2 was used. Funnel plots and Egger's regression test were applied to evaluate
Associations between Homocysteine, FolicAcid, Vitamin B12 and Alzheimer's Disease: Insights from Meta-Analyses. The associations between homocysteine (Hcy), folicacid, and vitamin B12 and Alzheimer's disease (AD) have gained much interest, while remaining controversial. We aim to perform meta-analyses to evaluate comprehensively: i) Hcy, folicacid, and vitamin B12 levels in AD patients in comparison with controls; and ii) the association between Hcy, folicacid, and vitamin B12 levels (...) and vitamin B12 levels further enlarged with increased age. Second, data suggests that high Hcy and low folate levels may correlate with increased risk of AD occurrence. The comprehensive meta-analyses not only confirmed higher Hcy, lower folicacid, and vitamin B12 levels in AD patients than controls, but also implicated that high Hcy and low folicacid levels may be risk factors of AD. Further studies are encouraged to elucidate mechanisms linking these conditions.
Periconceptional folicacid fortification for the risk of gestational hypertension and pre-eclampsia: a meta-analysis of prospective studies. Published literatures report controversial results about the association of folicacid-containing multivitamins with gestational hypertension and pre-eclampsia. A comprehensive search was performed to identify related prospective studies to assess the effect of folicacid fortification on gestational hypertension and pre-eclampsia. The Q test and I(2 (...) ) statistic were used to examine between-study heterogeneity. Fixed or random effects models were selected based on study heterogeneity. A funnel plot and modified Egger linear regression test were used to estimate publication bias. Eleven studies conformed to the criteria. Pooled results indicated that folicacid fortification alone was not associated with the occurrence of gestational hypertension [relative risk (RR) = 1.03, 95% confidence interval (CI): 0.98-1.09, P = 0.267] and pre-eclampsia (RR
Plasma Homocysteine, Serum FolicAcid, Serum Vitamin B12, Serum Vitamin B6, MTHFR, and Risk of Normal-Tension Glaucoma. This meta-analysis aims to comprehensively evaluate the association between total homocysteine (tHcy) levels, serum folicacid, vitamin B12, vitamin B6 levels, methylenetetrahydrofolate reductase (MTHFR) C677T genotype, and risk of normal-tension glaucoma (NTG).A systematic search of the EMBASE and PubMed databases was performed to evaluate plasma tHcy levels, serum folicacid (...) , B vitamins' mean difference, and odds ratios of MTHFR C677T genotype between cases and controls.A total of 7 studies including 458 cases and 555 controls meeting the inclusion criteria were involved in this meta-analysis. There were 4 studies for tHcy (149 cases and 148 controls), 2 studies for vitamin B6, vitamin B12, and folate (90 cases and 82 controls), and 4 studies for MTHFR (343 cases and 449 controls). Overall, the mean plasma tHcy levels, serum folicacids, vitamin B12, and vitamin B6
Folicacid supplements and colorectal cancer risk: meta-analysis of randomized controlled trials. Numerous studies have investigated the effects of folicacid supplementation on colorectal cancer risk, but conflicting results were reported. We herein performed a meta-analysis based on relevant studies to reach a more definitive conclusion. The PubMed and Embase databases were searched for quality randomized controlled trials (RCTs) published before October 2014. Eight articles met the inclusion (...) criteria and were subsequently analyzed. The results suggested that folicacid treatment was not associated with colorectal cancer risk in the total population (relative risk [RR] = 1.00, 95% confidence interval [CI] = 0.82-1.22, P = 0.974). Moreover, no statistical effect was identified in further subgroup analyses stratified by ethnicity, gender, body mass index (BMI) and potential confounding factors. No significant heterogeneity or publication bias was observed. In conclusion, our meta-analysis
Efficacy of FolicAcid Therapy in Primary Prevention of Stroke Among Adults With Hypertension in China: The CSPPT Randomized Clinical Trial. Uncertainty remains about the efficacy of folicacid therapy for the primary prevention of stroke because of limited and inconsistent data.To test the primary hypothesis that therapy with enalapril and folicacid is more effective in reducing first stroke than enalapril alone among Chinese adults with hypertension.The China Stroke Primary Prevention Trial (...) , a randomized, double-blind clinical trial conducted from May 19, 2008, to August 24, 2013, in 32 communities in Jiangsu and Anhui provinces in China. A total of 20,702 adults with hypertension without history of stroke or myocardial infarction (MI) participated in the study.Eligible participants, stratified by MTHFR C677T genotypes (CC, CT, and TT), were randomly assigned to receive double-blind daily treatment with a single-pill combination containing enalapril, 10 mg, and folicacid, 0.8 mg (n = 10,348
Maternal folicAcid supplementation and the risk of congenital heart defects in offspring: a meta-analysis of epidemiological observational studies. Epidemiological studies have reported conflicting results regarding the association between maternal folicacid supplementation and the risk of congenital heart defects (CHDs). However, a meta-analysis of the association between maternal folicacid supplementation and CHDs in offspring has not been conducted. We searched the MEDLINE and EMBASE